bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com

StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE) in a research note issued to investors on Wednesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Other research analysts have also issued reports about the stock. Barclays decreased their price target on shares of bluebird bio from $4.00 to $2.00 and set an “overweight” rating for the company in a research note on Friday, November 15th. Robert W. Baird decreased their price target on shares of bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a research note on Thursday, August 15th. Cantor Fitzgerald reiterated a “neutral” rating on shares of bluebird bio in a research note on Monday, September 16th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $4.00 price target on shares of bluebird bio in a research note on Friday, November 15th. Finally, JPMorgan Chase & Co. lowered shares of bluebird bio from a “neutral” rating to an “underweight” rating in a research note on Friday, November 15th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $3.03.

bluebird bio Trading Up 2.6 %

NASDAQ:BLUE opened at $0.46 on Wednesday. The company has a 50-day moving average price of $0.45 and a 200-day moving average price of $0.72. bluebird bio has a 12 month low of $0.29 and a 12 month high of $5.53. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. The stock has a market cap of $88.51 million, a price-to-earnings ratio of -0.24 and a beta of 0.72.

Shares of bluebird bio are set to reverse split on the morning of Friday, December 13th. The 1-20 reverse split was announced on Wednesday, December 4th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, December 12th.

bluebird bio (NASDAQ:BLUE) last posted its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) EPS for the quarter. bluebird bio had a negative return on equity of 322.46% and a negative net margin of 565.74%. The company had revenue of $18.57 million during the quarter. Equities analysts predict that bluebird bio will post -1.35 EPS for the current year.

Institutional Trading of bluebird bio

Institutional investors and hedge funds have recently bought and sold shares of the company. Allegheny Financial Group LTD bought a new stake in bluebird bio during the 2nd quarter valued at about $25,000. Verition Fund Management LLC bought a new stake in bluebird bio during the 3rd quarter valued at about $42,000. SG Americas Securities LLC boosted its holdings in shares of bluebird bio by 152.4% during the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 74,185 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of bluebird bio by 113.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock valued at $71,000 after acquiring an additional 29,113 shares during the last quarter. Finally, Captrust Financial Advisors boosted its holdings in shares of bluebird bio by 48.2% during the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 77,293 shares during the last quarter. 87.43% of the stock is currently owned by institutional investors.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.